A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
-
Politics
Lai takes advice from high schoolers on fighting Chinese disinformation
05/30/2026 08:43 PM -
Business
Opposition fast-tracks air pollution bills despite government, industry concerns
05/30/2026 08:35 PM -
Business
LPG prices to remain unchanged in June: CPC
05/30/2026 07:07 PM -
Society
Taiwan's NGOs quit U.S. fundraising platform over 'Chinese Taipei' designation
05/30/2026 06:35 PM -
Business
Taiwan's CPC to leave domestic gasoline, diesel prices steady next week
05/30/2026 05:40 PM